- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07621094
Intraosseous Antibiotics for Osseointegration (IOAOI)
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The goal of this multi-center prospective trial is to assess the characteristics of infection among patients with osseointegrated prosthesis and the safety and effectiveness of intraosseous antibiotic delivery.
Participants will enroll in an observational arm. Participants who require surgery for infection may enroll in an interventional arm assessing the safety and feasibility of intraosseous antibiotic administration as a potential treatment for infection.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Christine Churchill, MA
- Número de teléfono: 704-355-6947
- Correo electrónico: christine.churchill@advocatehealth.org
Ubicaciones de estudio
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- University of Colorado Anschutz Medical Campus
-
Contacto:
- Mohamed Awad, MD
- Número de teléfono: 706-832-9969
- Correo electrónico: mohamed.awad@cuanschutz.edu
-
Investigador principal:
- Danielle Melton, MD
-
-
New York
-
New York, New York, Estados Unidos, 10021
- Hospital for Special Surgery
-
Contacto:
- Lediona Ardolli
- Número de teléfono: 646-714-6362
- Correo electrónico: ardollil@hss.edu
-
Investigador principal:
- S. Robert Rozbruch, MD
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28203
- Atrium Health Carolinas Medical Center
-
Investigador principal:
- Joseph R Hsu, MD
-
Contacto:
- Rachel B Seymour, PhD
- Número de teléfono: 704-441-5365
- Correo electrónico: Rachel.Seymour@advocatehealth.org
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- University of Pennsylvania Perelman School of Medicine
-
Investigador principal:
- Benjamin Potter, MD
-
Contacto:
- Annamarie Horan, PhD
- Número de teléfono: 215-847-0132
- Correo electrónico: horana@pennmedicine.upenn.edu
-
-
Texas
-
San Antonio, Texas, Estados Unidos, 78229
- UT Health San Antonio
-
Contacto:
- Nick Lucio, BA
- Número de teléfono: 210-567-5142
- Correo electrónico: luciond@uthscsa.edu
-
Investigador principal:
- Joseph Alderete, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Treated with osseointegration for transfemoral, transhumeral, or transtibial amputation and presenting with concern for surgical site infection
- >18 years of age
Exclusion Criteria:
- Unable to follow up at site for 1 year
- Patients that speak neither English nor Spanish
- <18 years of age
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Sin intervención: Observational
Patients that do not require surgery for infection
|
|
|
Experimental: Intraosseous Antibiotics for Osseointegration
Patients that require surgery for infection
|
After debridement, patients will receive intraosseous (IO) vancomycin 500mg in 150ml of normal saline during surgery.
The solution will be prepared by the hospital pharmacy and administered via an IO cannula.
The cannula will be placed proximal to the intramedullary fixture.
In cases where a tourniquet can be utilized proximal to the IO cannula, the antibiotic is delivered as a bolus.
Tourniquet must be up for 1 hour after installation of the IO cases where the residual limb is too short to allow tourniquet (pneumatic or elastic) proximal to the IO cannula, the intraosseous antibiotic must be infused at a rate not to exceed 10mg/min or less.
This can be accomplished by connecting intravenous tubing to the antibiotic mixture and the IO cannula.
In cases without a tourniquet, IO infusion should begin during the irrigation phase and continue through the complete closure of the wound, since it requires a significant amount of time 50-60 min.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Patients Who Develop Wound Dehiscence
Periodo de tiempo: Week 2
|
Wound Dehiscence is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart.
It is Yes/No.
|
Week 2
|
|
Number of Patients Who Develop Wound Dehiscence
Periodo de tiempo: Week 6
|
Wound Dehiscence is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart.
It is Yes/No.
|
Week 6
|
|
Number of Patients Who Develop Wound Dehiscence
Periodo de tiempo: Month 3
|
Wound Dehiscence is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart.
It is Yes/No.
|
Month 3
|
|
Number of Patients Who Develop Wound Dehiscence
Periodo de tiempo: Month 6
|
Wound Dehiscence is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart.
It is Yes/No.
|
Month 6
|
|
Number of Patients Who Develop Wound Dehiscence
Periodo de tiempo: Month 12
|
Wound Dehiscence is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart.
It is Yes/No.
|
Month 12
|
|
Number of Patients Who Develop Superficial Infection
Periodo de tiempo: Week 2
|
Superficial Infection is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart.
It is yes/no.
|
Week 2
|
|
Number of Patients Who Develop Superficial Infection
Periodo de tiempo: Week 6
|
Superficial Infection is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart.
It is yes/no.
|
Week 6
|
|
Number of Patients Who Develop Superficial Infection
Periodo de tiempo: Month 3
|
Superficial Infection is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart.
It is yes/no.
|
Month 3
|
|
Number of Patients Who Develop Superficial Infection
Periodo de tiempo: Month 6
|
Superficial Infection is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart.
It is yes/no.
|
Month 6
|
|
Number of Patients Who Develop Superficial Infection
Periodo de tiempo: Month 12
|
Superficial Infection is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart.
It is yes/no.
|
Month 12
|
|
Number of Patients Who Develop Deep Surgical Site Infection
Periodo de tiempo: Week 2
|
Number of participants in each group who develop surgical site infection as defined by the criteria establish by the Centers for Disease Control and Prevention (CDC).
The CDC criteria define deep as occurring within 30 or 90 days after the procedure.
However, we will continue to follow patients for 12 months and document any infections and other complications during this period.
|
Week 2
|
|
Number of Patients Who Develop Deep Surgical Site Infection
Periodo de tiempo: Week 6
|
Number of participants in each group who develop surgical site infection as defined by the criteria establish by the Centers for Disease Control and Prevention (CDC).
The CDC criteria define deep as occurring within 30 or 90 days after the procedure.
However, we will continue to follow patients for 12 months and document any infections and other complications during this period.
|
Week 6
|
|
Number of Patients Who Develop Deep Surgical Site Infection
Periodo de tiempo: Month 3
|
Number of participants in each group who develop surgical site infection as defined by the criteria establish by the Centers for Disease Control and Prevention (CDC).
The CDC criteria define deep as occurring within 30 or 90 days after the procedure.
However, we will continue to follow patients for 12 months and document any infections and other complications during this period.
|
Month 3
|
|
Number of Patients Who Develop Deep Surgical Site Infection
Periodo de tiempo: Month 6
|
Number of participants in each group who develop surgical site infection as defined by the criteria establish by the Centers for Disease Control and Prevention (CDC).
The CDC criteria define deep as occurring within 30 or 90 days after the procedure.
However, we will continue to follow patients for 12 months and document any infections and other complications during this period.
|
Month 6
|
|
Number of Patients Who Develop Deep Surgical Site Infection
Periodo de tiempo: Month 12
|
Number of participants in each group who develop surgical site infection as defined by the criteria establish by the Centers for Disease Control and Prevention (CDC).
The CDC criteria define deep as occurring within 30 or 90 days after the procedure.
However, we will continue to follow patients for 12 months and document any infections and other complications during this period.
|
Month 12
|
|
Number of Patients With Treatment Failure
Periodo de tiempo: Week 2
|
Treatment failure is defined as explant of the OI implant for any reason.
Treatment failure will also be defined as additional surgical complications, wound complications, need for chronic antibiotic suppression, readmission, and reoperation.
|
Week 2
|
|
Number of Patients With Treatment Failure
Periodo de tiempo: Week 6
|
Treatment failure is defined as explant of the OI implant for any reason.
Treatment failure will also be defined as additional surgical complications, wound complications, need for chronic antibiotic suppression, readmission, and reoperation.
|
Week 6
|
|
Number of Patients With Treatment Failure
Periodo de tiempo: Month 3
|
Treatment failure is defined as explant of the OI implant for any reason.
Treatment failure will also be defined as additional surgical complications, wound complications, need for chronic antibiotic suppression, readmission, and reoperation.
|
Month 3
|
|
Number of Patients With Treatment Failure
Periodo de tiempo: Month 6
|
Treatment failure is defined as explant of the OI implant for any reason.
Treatment failure will also be defined as additional surgical complications, wound complications, need for chronic antibiotic suppression, readmission, and reoperation.
|
Month 6
|
|
Number of Patients With Treatment Failure
Periodo de tiempo: Month 12
|
Treatment failure is defined as explant of the OI implant for any reason.
Treatment failure will also be defined as additional surgical complications, wound complications, need for chronic antibiotic suppression, readmission, and reoperation.
|
Month 12
|
|
Rate of Adverse Events
Periodo de tiempo: Week 2
|
The proportion of participants experiencing ≥1 adverse event during the study period will be assessed to evaluate safety.
Adverse events include any unfavorable or unintended medical occurrence, regardless of relatedness, including surgical, infectious, wound-related, or systemic events.
Events will be collected prospectively and categorized by severity and relatedness.
|
Week 2
|
|
Rate of Adverse Events
Periodo de tiempo: Week 6
|
The proportion of participants experiencing ≥1 adverse event during the study period will be assessed to evaluate safety.
Adverse events include any unfavorable or unintended medical occurrence, regardless of relatedness, including surgical, infectious, wound-related, or systemic events.
Events will be collected prospectively and categorized by severity and relatedness.
|
Week 6
|
|
Rate of Adverse Events
Periodo de tiempo: Month 3
|
The proportion of participants experiencing ≥1 adverse event during the study period will be assessed to evaluate safety.
Adverse events include any unfavorable or unintended medical occurrence, regardless of relatedness, including surgical, infectious, wound-related, or systemic events.
Events will be collected prospectively and categorized by severity and relatedness.
|
Month 3
|
|
Rate of Adverse Events
Periodo de tiempo: Month 6
|
The proportion of participants experiencing ≥1 adverse event during the study period will be assessed to evaluate safety.
Adverse events include any unfavorable or unintended medical occurrence, regardless of relatedness, including surgical, infectious, wound-related, or systemic events.
Events will be collected prospectively and categorized by severity and relatedness.
|
Month 6
|
|
Rate of Adverse Events
Periodo de tiempo: Month 12
|
The proportion of participants experiencing ≥1 adverse event during the study period will be assessed to evaluate safety.
Adverse events include any unfavorable or unintended medical occurrence, regardless of relatedness, including surgical, infectious, wound-related, or systemic events.
Events will be collected prospectively and categorized by severity and relatedness.
|
Month 12
|
|
Rate of antibiotic-complications
Periodo de tiempo: Week 2
|
The proportion of participants experiencing ≥1 antibiotic-related complication during treatment will be assessed.
Complications include clinically significant events attributable to antibiotic exposure (e.g., allergic reactions, gastrointestinal intolerance, hepatotoxicity, nephrotoxicity, hematologic abnormalities, or local administration-related reactions).
Events will be identified through clinical assessment, laboratory data, and medical record review.
|
Week 2
|
|
Rate of antibiotic-complications
Periodo de tiempo: Week 6
|
The proportion of participants experiencing ≥1 antibiotic-related complication during treatment will be assessed.
Complications include clinically significant events attributable to antibiotic exposure (e.g., allergic reactions, gastrointestinal intolerance, hepatotoxicity, nephrotoxicity, hematologic abnormalities, or local administration-related reactions).
Events will be identified through clinical assessment, laboratory data, and medical record review.
|
Week 6
|
|
Rate of antibiotic-complications
Periodo de tiempo: Month 3
|
The proportion of participants experiencing ≥1 antibiotic-related complication during treatment will be assessed.
Complications include clinically significant events attributable to antibiotic exposure (e.g., allergic reactions, gastrointestinal intolerance, hepatotoxicity, nephrotoxicity, hematologic abnormalities, or local administration-related reactions).
Events will be identified through clinical assessment, laboratory data, and medical record review.
|
Month 3
|
|
Rate of antibiotic-complications
Periodo de tiempo: Month 6
|
The proportion of participants experiencing ≥1 antibiotic-related complication during treatment will be assessed.
Complications include clinically significant events attributable to antibiotic exposure (e.g., allergic reactions, gastrointestinal intolerance, hepatotoxicity, nephrotoxicity, hematologic abnormalities, or local administration-related reactions).
Events will be identified through clinical assessment, laboratory data, and medical record review.
|
Month 6
|
|
Rate of antibiotic-complications
Periodo de tiempo: Month 12
|
The proportion of participants experiencing ≥1 antibiotic-related complication during treatment will be assessed.
Complications include clinically significant events attributable to antibiotic exposure (e.g., allergic reactions, gastrointestinal intolerance, hepatotoxicity, nephrotoxicity, hematologic abnormalities, or local administration-related reactions).
Events will be identified through clinical assessment, laboratory data, and medical record review.
|
Month 12
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Patient-Reported Outcomes Measurement Information System (PROMIS -29)
Periodo de tiempo: 2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
The PROMIS-29 is a free to use, publicly available generic health related quality of life measure that includes seven domains: depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities.
A 5-point Likert scale is used for each question and norm-based total scores (range 0-100) have been calculated so that 50 represents the mean and one standard deviation is 10 points.
Higher scores represent better function.
|
2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
|
Veterans RAND 12 (VR-12) Health Survey - Physical Component Score
Periodo de tiempo: 2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
The VR-12 is a measure of global health that corresponds to seven domains: general health, physical functioning, role limitations, pain, fatigue, social functioning, and mental health.
Together, these items are summarized into a Physical Component Score.
The mean score is 50 with a standard deviation of 10.
Higher scores indicate better average health (higher than 50 means better than average health, below 50 means below average health).
|
2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
|
Veterans Rand 12 (VR12) Health Survey - Mental Component Score
Periodo de tiempo: 2 weeks, 6-weeks, 3-months, 6-months, 12-months
|
The VR-12 is a measure of global health that corresponds to seven domains: general health, physical functioning, role limitations, pain, fatigue, social functioning, and mental health.
Together, these items are summarized into a Mental Component Score.
The mean score is 50 with a standard deviation of 10.
Higher scores indicate better average health (higher than 50 means better than average health, below 50 means below average health).
|
2 weeks, 6-weeks, 3-months, 6-months, 12-months
|
|
Pain - Numeric Rating Scale
Periodo de tiempo: 2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
A scale from 0-10, where 0 is no pain and 10 is the worst pain.
|
2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
|
Pain - Brief Pain Inventory (BPI)
Periodo de tiempo: 2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
The BPI is a commonly used, validated 15-item measure of pain intensity and interference with daily life.
There is a pain severity score and a pain interference score.
Both are 0-10, with 0 being no pain and 10 being worst pain imaginable (for pain severity) and 0 being does not interfere and 10 being completely interfered (for pain interference).
Lower scores are better.
|
2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Joseph R Hsu, MD, Wake Forest University Health Sciences
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- IRB00147620
- 40010222 (Otro identificador: Department of Defense)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .